Navigation Links
An Improved Dry Eye Medication - ICAP Ocean Tomo Announces Auction of a New Collyrium From Aqueous Pharma Limited

CHICAGO, March 17, 2011 /PRNewswire/ -- Developed by Aqueous Pharma Limited and represented by ICAP Ocean Tomo, this patent pending technology discloses an improved formulation for treating eye disease, specifically chronic dry eye. The assets in this portfolio will be auctioned at ICAP Ocean Tomo's Spring 2011 Live IP Auction on March 31, 2011 in New York City.


Key Characteristics & Benefits

  • The formulation is an aqueous collyrium (i.e., an eye drop) that contains a proven secretagogue - an undecapeptide called eledoisin. Upon topical application, eledoisin is found to increase both tear secretion rate and tear volume.
  • The collyrium comprises an aqueous composition containing phospholipids (e.g. lecithin, dodecyl-phosphocholine, etc.) in a micellar form and eledoisin in an ester form.
  • Eledoisin was discovered in the salivary glands of certain Mediterranean species of octopuses and can now be produced synthetically.
  • Not only is the therapeutic effect more pronounced but, the composition becomes much more stable with the presence of phospholipid micelles.
  • This ophthalmic formulation has a beneficial effect on the damaged epithelial surface of eyes with minimal side effects, such as chemosis (i.e., swelling of surface eye membranes) and hyperemia (i.e., increased blood flow around eye tissues).

Market Potential

This lot should be of interest to pharmaceutical companies, drug manufacturers, and others in the healthcare field.

  • The US market for dry eye disease treatment was estimated to be $1.7 billion in 2009 and is expected to be more than $2.4 billion by 2014.(1)

To learn more about the assets available for sale in this portfolio:

Contact Dean Becker of ICAP Ocean Tomo at

About ICAP Ocean Tomo LLC

ICAP Ocean Tomo is the intellectual property brokerage division of ICAP and the world's premier patent auction firm.

About ICAP

ICAP is the world's premier interdealer broker and provider of post trade services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, foreign exchange, emerging markets, equities and equity derivatives through voice and electronic networks. ICAP plc was added to the FTSE 100 Index on 30 June 2006. For more information go to


Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MicroConstants Completes Installation of Latest LC/MS/MS Technology to Achieve Improved Sensitivity in Bioanalytical Method Development
2. Perceptive Informatics Integrates Medical Imaging Tracking with RTSM Technologies for Streamlined Workflow, Improved Data Quality
3. NexBio’s DAS181 (Fludase®*) Improved Symptoms in a Severely Immunocompromised Patient with Parainfluenza Pneumonitis
4. Fujitsu to Showcase New Document Imaging Technologies for Improved Information Sharing and Record Keeping at HIMSS 2011
5. Enbrel® (etanercept) Significantly Improved Scalp Involvement in Patients with Moderate to Severe Plaque Psoriasis
6. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
7. Arcadia Resources Announces Improved Fiscal 2011 Second Quarter Results
8. IRIDEX Reports Improved Third Quarter 2010 Financial Results
9. Study Published This Week in Alzheimers & Dementia: The Journal of the Alzheimers Association Shows that Algal DHA Improved Memory and Learning in Healthy Adults Age 55 and Older
10. Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
11. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
Post Your Comments:
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
Breaking Medicine News(10 mins):